Hydrogel-Based 3D Model of Patient-Derived Prostate Xenograft Tumors Suitable for Drug Screening

Simple item page
dc.citation.firstpage2040
dc.citation.issueNumber7
dc.citation.journalTitleMolecular Pharmaceutics
dc.citation.lastpage2050
dc.citation.volumeNumber11
dc.contributor.authorFong, Eliza L.S.
dc.contributor.authorMartinez, Mariane
dc.contributor.authorYang, Jun
dc.contributor.authorMikos, Antonios G.
dc.contributor.authorNavone, Nora M.
dc.contributor.authorHarrington, Daniel Anton
dc.contributor.authorFarach-Carson, Mary C.
dc.date.accessioned2015-10-28T19:04:03Z
dc.date.available2015-10-28T19:04:03Z
dc.date.issued2014
dc.description.abstractThe lack of effective therapies for bone metastatic prostate cancer (PCa) underscores the need for accurate models of the disease to enable the discovery of new therapeutic targets and to test drug sensitivities of individual tumors. To this end, the patient-derived xenograft (PDX) PCa model using immunocompromised mice was established to model the disease with greater fidelity than is possible with currently employed cell lines grown on tissue culture plastic. However, poorly adherent PDX tumor cells exhibit low viability in standard culture, making it difficult to manipulate these cells for subsequent controlled mechanistic studies. To overcome this challenge, we encapsulated PDX tumor cells within a three-dimensional hyaluronan-based hydrogel and demonstrated that the hydrogel maintains PDX cell viability with continued native androgen receptor expression. Furthermore, a differential sensitivity to docetaxel, a chemotherapeutic drug, was observed as compared to a traditional PCa cell line. These findings underscore the potential impact of this novel 3D PDX PCa model as a diagnostic platform for rapid drug evaluation and ultimately push personalized medicine toward clinical reality.
dc.identifier.citationFong, Eliza L.S., Martinez, Mariane, Yang, Jun, et al.. "Hydrogel-Based 3D Model of Patient-Derived Prostate Xenograft Tumors Suitable for Drug Screening." <i>Molecular Pharmaceutics,</i> 11, no. 7 (2014) American Chemical Society: ﾠ2040-2050. http://dx.doi.org/10.1021/mp500085p.
dc.identifier.doihttp://dx.doi.org/10.1021/mp500085p
dc.identifier.urihttps://hdl.handle.net/1911/81940
dc.language.isoeng
dc.publisherAmerican Chemical Society
dc.rightsThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
dc.rights.urihttp://pubs.acs.org/page/policy/authorchoice_termsofuse.html
dc.subject.keywordpatient-derived xenograft
dc.subject.keywordhydrogel
dc.subject.keywordtumor
dc.subject.keyworddrug
dc.subject.keywordprostate cancer
dc.titleHydrogel-Based 3D Model of Patient-Derived Prostate Xenograft Tumors Suitable for Drug Screening
dc.typeJournal article
dc.type.dcmiText
dc.type.publicationpublisher version
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
mp500085p.pdf
Size:
2.41 MB
Format:
Adobe Portable Document Format
Description:
Article
Download
Thumbnail Image
Name:
mp500085p_si_001.pdf
Size:
292.79 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Information
Download
Collections
Faculty Publications
Biochemistry and Cell Biology Publications
Bioengineering Publications